ConductScience.org, home

Paper40316348

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.

Price T and 19 others. BMJ Open, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours. Papers, record 40316348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40316348

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
PubMed
Journal
BMJ Open
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase I, Multicenter Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-05-08
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Price TTimothyhttps://orcid.org/0000-0002-3922-2693
2Lugowska IIwona
3Chawla SPSant P
4Falchook GGerald
5Subbiah VVivek
6Monzon JGJose G
7Arkenau HTHendrik-Tobias
8Hui MMun
9Kuboki YYasutoshihttps://orcid.org/0000-0003-3675-953X
10Dziadziuszko RRafal
11Shibaki RRyota
12Hong MHMin Heehttps://orcid.org/0000-0003-3490-2195
13Tan DDaniel
14Rocha Lima CMCaio Max
15Wang KKejia
16Hindoyan AAntreas
17Shi WWeibing
18Wong HHansen
19Kistler MMira
20Prenen HHans

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
NeoplasmsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Lung NeoplasmsMajor topic
Immune Checkpoint InhibitorsMajor topic
Humans
Female
Male
Middle Aged
Aged
Adult
Aged, 80 and over
Dose-Response Relationship, Drug

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03853109AMG 404 in Patients With Advanced Solid TumorsBackgroundYes

Source ClinicalTrials.gov

Download CSV of trials

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120935021A modified toxicity probability interval method for dose-finding trials.Clin Trials2010https://conductscience.org/library/papers/20935021PubMed
228650338IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017https://conductscience.org/library/papers/28650338PubMed
326952546Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet2016https://conductscience.org/library/papers/26952546PubMed
426028255PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med2015https://conductscience.org/library/papers/26028255PubMed
527928714Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.Invest New Drugs2017https://conductscience.org/library/papers/27928714PubMed
636587500Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.Int Immunopharmacol2023https://conductscience.org/library/papers/36587500PubMed
728916617Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.Clin Cancer Res2017https://conductscience.org/library/papers/28916617PubMed
830139382Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.Mol Cancer2018https://conductscience.org/library/papers/30139382PubMed
935778636The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.Gastric Cancer2022https://conductscience.org/library/papers/35778636PubMed
1028734759Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.Lancet Oncol2017https://conductscience.org/library/papers/28734759PubMed
1128187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
1235228677Biomarkers of response to PD-1 pathway blockade.Br J Cancer2022https://conductscience.org/library/papers/35228677PubMed
1327117531Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.Ann Oncol2016https://conductscience.org/library/papers/27117531PubMed
1433580222PD-L1 as a biomarker of response to immune-checkpoint inhibitors.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/33580222PubMed
1533264544Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med2020https://conductscience.org/library/papers/33264544PubMed
1623470321Molecular mechanisms of T cell co-stimulation and co-inhibition.Nat Rev Immunol2013https://conductscience.org/library/papers/23470321PubMed
1732919526
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol2020https://conductscience.org/library/papers/32919526PubMed
1819620385Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.J Clin Pharmacol2009https://conductscience.org/library/papers/19620385PubMed
1919095437Individual patient data analysis to assess modifications to the RECIST criteria.Eur J Cancer2009https://conductscience.org/library/papers/19095437PubMed
2032917410PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.Gynecol Oncol2020https://conductscience.org/library/papers/32917410PubMed

See all 43 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40316348

GET https://conductscience.org/api/papers/v1/40316348/references?page=2